Medical

JJ Mifsud, Brad Aufderheide

Oncology engagement is evolving. Learn how AI, real-world data, and digital behaviors are reshaping how we connect with time-pressed HCPs in a fast-moving field.

Amy Gómez

See how AI, telemedicine, and digital screening are transforming cancer care—and why true equity demands broadband access, trust, and systemic investment.

Alfred Whitehead

AI and automation are transforming MLR review by improving efficiency, reducing rework, and enabling compliant content reuse. Discover how to unlock speed without sacrificing accur...

JJ Mifsud

Focus groups can’t keep pace with the urgency of oncology. AI-driven simulations are changing the game—delivering insights on how oncologists respond to efficacy, safety, and compe...

Steve Palmieri

Pharma is evolving. Explore key shifts from Pharma USA 2025, from operationalizing precision to building trust, access, and human-centric engagement.

Scott Kopetz, Jasmine Singh

24 de março de 2025

Jasmine Singh, EVP Medical Strategy, Klick Health, sits down with Dr. Scott Kopetz from MD Anderson to talk about minimal residual disease and why cancer that doesn’t show up on a ...

Robert Groebel III

Klick’s 5P framework empowers medical affairs teams to enhance DOL engagement using strategic profiling, planning, partnering, and social media to drive lasting medical impact.

Cassandra Carroll, Bahar Ameri

The FDA is scrutinizing celebrity pharma ads. Learn how Klick ensures compliance by balancing authenticity, risk communication, and efficacy claims in influencer marketing.

Cassandra Carroll, Tim Mitchell

This overview clarifies DOL engagement best practices, ensuring collaborations are transparent, credible, and anchored in long-term trust.

Wes Spence

AI is transforming pharma, but adoption challenges remain. From scaling AI literacy to balancing innovation with compliance, discover key insights from the “Age of AI, Europe.”

Quentin O'Brien

​​This POV highlights Bluesky as a new frontier for medical affairs, enabling scientific exchange, KOL/DOL engagement, and data amplification through unique features.

Brad Aufderheide

Test your rare disease marketing knowledge. Discover myths, facts, and best practices for engaging patients early, addressing unmet needs, and effectively amplifying their voices.

Brad Aufderheide

Oncology is looking more and more like a rare disease in its treatment, with a shift towards hyper-personalized care and deploying digital tools that empower patients, advocates, a...

Brad Aufderheide

Discover the true impact of rare disease and the urgent need for innovation through data that challenges misconceptions and highlights unmet needs.

Brad Aufderheide

Review our recommendations for a unique approach to rare disease marketing to recognize the distinct challenges and nuances that set it apart from traditional healthcare marketing ...

Quentin O'Brien

AI is transforming medical affairs and driving engagement. To stay ahead, teams must embrace AI, upskill, and adapt. Read the full article for post-conference insights from the 202...

Jasmine Singh

Explore the Klick Mediverse, where medical, scientific, and regulatory expertise converge to transform healthcare commercialization.

Stakeholder Engagement Team

Klick’s Stakeholder Maturity Index (SMI) framework provides a structured approach to stakeholder engagement strategies.

Stakeholder Engagement Team

Patients, care partners, advocacy groups, and even government agencies can be part of a holistic stakeholder engagement strategy. Does your ecosystem go beyond the expected?

Stakeholder Engagement Team

The Stakeholder Maturity Index (SMI) is a strategic tool designed to enhance stakeholder engagement by assessing four key areas.

Stakeholder Engagement Team

The Stakeholder Maturity Index (SMI) Workbook is a comprehensive guide that helps organizations elevate their stakeholder engagement strategies.

Stakeholder Engagement Team

The Stakeholder Maturity Index (SMI) evaluates your organization’s KOL-engagement strategy and provides personalized insights to enhance stakeholder relationships.

Brad Aufderheide

The oncology landscape is undergoing a revolution, driven by cutting-edge innovations in personalized medicine, AI-powered decision-making, and more.

Nicole Watts, Sean Lim

In today’s pharmaceutical landscape, trust is crucial. FDA research shows that HCPs are more likely to prescribe when pharma promotional materials emphasize transparency.

Tim Mitchell

Looking for actionable strategies to harness the influence of digital opinion leaders in healthcare?